The Organon board of directors has approved the deal. The transaction is expected to close in the first quarter of 2026, subject to required regulatory approvals. “I am incredibly proud of the work ...

Net proceeds will be applied to debt reduction, advancing Organon’s ongoing deleveraging efforts Positions Organon for future investment in growth opportunities with a focus on women’s health ...

The JADA ® System is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. Organon (NYSE: OGN) is a global ...

The women’s health company Organon has put forward the first real-world data collected from its Jada system, a device used to help stop excessive and potentially life-threatening bleeding following ...

Organon & Co. OGN announced the completion of the divestiture of its JADA System to Laborie Medical Technologies Corp. The deal is worth up to $465 million, including $440 million paid at closing and ...

Laborie Medical Technologies Corp. secured a new gem for its maternal health with the acquisition of the Jada system from Organon & Co. The terms of the deal, first announced in November, included ...

Please provide your email address to receive an email when new articles are posted on . The JADA system decreased abnormal postpartum uterine bleeding in vaginal and cesarean birth, regardless of ...

Investor AB ( ($SE:INVE.A) ) has shared an announcement. Patricia Industries’ subsidiary, Laborie, is set to acquire the JADA System from Organon, a medical device ...

The JADA® System for treatment of abnormal postpartum uterine bleeding, and the team behind the product, join Laborie, strengthening the company's commitment to improving maternal health. Joining an ...

Organon is selling its JADA post-partum haemorrhage (PPH) treatment system to Laborie Medical in a deal valued at up to $465m. The US-based company will receive $440m at the deal’s closing, with ...